Baxter International Company Profile (NYSE:BAX)

About Baxter International (NYSE:BAX)

Baxter International logoBaxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:BAX
  • CUSIP: 07181310
  • Web:
  • Market Cap: $31.88 billion
  • Outstanding Shares: 543,669,000
Average Prices:
  • 50 Day Moving Avg: $55.33
  • 200 Day Moving Avg: $49.79
  • 52 Week Range: $42.22 - $59.41
  • Trailing P/E Ratio: 17.35
  • Foreward P/E Ratio: 22.91
  • P/E Growth: 2.01
Sales & Book Value:
  • Annual Revenue: $10.26 billion
  • Price / Sales: 3.11
  • Book Value: $16.00 per share
  • Price / Book: 3.67
  • Annual Dividend: $0.52
  • Dividend Yield: 1.1%
  • EBIDTA: $2.13 billion
  • Net Margins: 48.85%
  • Return on Equity: 12.35%
  • Return on Assets: 6.58%
  • Debt-to-Equity Ratio: 0.33%
  • Current Ratio: 2.53%
  • Quick Ratio: 1.93%
  • Average Volume: 3.08 million shs.
  • Beta: 0.77
  • Short Ratio: 3.27

Frequently Asked Questions for Baxter International (NYSE:BAX)

What is Baxter International's stock symbol?

Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."

How often does Baxter International pay dividends? What is the dividend yield for Baxter International?

Baxter International announced a quarterly dividend on Tuesday, May 2nd. Investors of record on Friday, June 2nd will be given a dividend of $0.16 per share on Monday, July 3rd. This represents a $0.64 dividend on an annualized basis and a yield of 1.09%. The ex-dividend date is Wednesday, May 31st. This is a positive change from Baxter International's previous quarterly dividend of $0.13. View Baxter International's Dividend History.

How were Baxter International's earnings last quarter?

Baxter International Inc (NYSE:BAX) posted its quarterly earnings data on Wednesday, April, 26th. The company reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.07. The company had revenue of $2.48 billion for the quarter, compared to analysts' expectations of $2.43 billion. Baxter International had a net margin of 48.85% and a return on equity of 12.35%. The business's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.36 earnings per share. View Baxter International's Earnings History.

When will Baxter International make its next earnings announcement?

Baxter International is scheduled to release their next quarterly earnings announcement on Monday, July, 24th 2017. View Earnings Estimates for Baxter International.

What guidance has Baxter International issued on next quarter's earnings?

Baxter International updated its FY17 earnings guidance on Wednesday, April, 26th. The company provided EPS guidance of $2.20-$2.28 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.17. Baxter International also updated its Q2 guidance to $0.55-$0.57 EPS.

Where is Baxter International's stock going? Where will Baxter International's stock price be in 2017?

12 brokers have issued 12 month target prices for Baxter International's shares. Their predictions range from $48.00 to $71.00. On average, they expect Baxter International's share price to reach $58.50 in the next year. View Analyst Ratings for Baxter International.

What are analysts saying about Baxter International stock?

Here are some recent quotes from research analysts about Baxter International stock:

  • 1. According to Zacks Investment Research, "Baxter reported impressive results in the first quarter of fiscal 2017, wherein adjusted earnings beat the Zacks Consensus Estimate. Furthermore, an upbeat guidance instills investor confidence in the stock. Over the past one year, the company outperformed the broader industry in terms of price movement. Of the major positives, a favorable product mix, stringent cost control and expanding operating margin are notable. Solid U.S. sales of IV therapies, IV access sets, select anesthesia and critical care products were the key catalysts. Growing adoption of Baxter’s ‘parenteral nutrition therapies’ and international bio-surgery products boosted sales at the Hospital products segment. The company also leverages on Automated Peritoneal Dialysis (APD) cyclers in the U.S. and HOMECHOICE CLARIA in international markets. We are also upbeat about the company’s recently signed definitive agreement to acquire Claris Injectables." (5/1/2017)
  • 2. Evercore ISI analysts commented, "BAX reported a solid finish to the year, beating consensus EPS estimates by double digits and initiating above ST EPS guidance. There were several highlights in the 4Q print, both on the topline and operating metrics that made us incrementally more positive on our 'turnaround + long term EPS power underappreciated by Street' thesis. From a revenue perspective, Renal came in above, and management highlighted continued strong adoption of AMIA PD with patient volumes doubling past few Qs (AMIA will be a key long term driver, and these trends bode well). While management guided to 3-4% growth for Renal in FY17, we think the low end of the guidance seems conservative given strength in underlying business + AMIA uptake. Within Fluid Systems, yet another strong high single digit showing highlighted the strength of Sigma Spectrum pump uptake. We found it interesting that guidance assumes 'flattening of Sigma pump in 2017', which we think is a conservative assumption (competitor BDX still expects pump share gains in FY17). Overall, the constant currency growth of ~2% seems conservative, with potential upside in the event of lack of competitive entrants for cyclo business. On the margin front, while FY17 OM of ~15% seems optically below the ~15.7% seen in 2H'16 levels (but equates to an expansion of ~150 bps over FY16), we note that it contemplates about 150 bps of headwinds related to cyclo competition, Fx & TSA rolling off. As such, the ~15% OM guidance seems prudent to us, with possible upside tied to lack of competitive cyclo entrants. Finally, the EPS guide of $2.10-2.18 does not assume any share repo and no contribution from Claris. In light of the impressive free cash increase (FY16 FCF came in 80% above original guidance; FY17 guide of >$1 Bn) and ~$1 Bn of repatriation, we see upside potential to EPS upside tied to capital deployment. All in, this was a solid print, and current levels provide a good entry point for long term holders (we note BAX repurchased $250 MM worth of shares at an avg. of $47.50 in 4Q, which is around current trading levels)." (2/1/2017)

Who are some of Baxter International's key competitors?

Who owns Baxter International stock?

Baxter International's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.63%), THIRD POINT LLC (8.50%), Vanguard Group Inc. (6.03%), State Street Corp (4.72%), Harris Associates L P (2.64%) and State Farm Mutual Automobile Insurance Co. (2.34%). Company insiders that own Baxter International stock include Albert P L Stroucken, Brik V Eyre, Carole J Shapazian, James R Gavin III, John D Forsyth, Jose E Almeida, Kornelis J Storm and Peter S Hellman. View Institutional Ownership Trends for Baxter International.

Who sold Baxter International stock? Who is selling Baxter International stock?

Baxter International's stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., AQR Capital Management LLC, Morgan Stanley, JPMorgan Chase & Co., American Century Companies Inc., Wellington Management Group LLP, Stevens Capital Management LP and Parametric Portfolio Associates LLC. Company insiders that have sold Baxter International stock in the last year include Albert P L Stroucken, Brik V Eyre, Carole J Shapazian, James R Gavin III, John D Forsyth and Peter S Hellman. View Insider Buying and Selling for Baxter International.

Who bought Baxter International stock? Who is buying Baxter International stock?

Baxter International's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Victory Capital Management Inc., CI Global Investments Inc., FMR LLC, Los Angeles Capital Management & Equity Research Inc., Marshall Wace North America L.P. and Harris Associates L P. View Insider Buying and Selling for Baxter International.

How do I buy Baxter International stock?

Shares of Baxter International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Baxter International stock cost?

One share of Baxter International stock can currently be purchased for approximately $58.64.

Analyst Ratings

Consensus Ratings for Baxter International (NYSE:BAX) (?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 5 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $58.50 (0.24% downside)

Analysts' Ratings History for Baxter International (NYSE:BAX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/16/2017Goldman Sachs Group IncReiterated RatingConviction-Buy$71.00HighView Rating Details
5/1/2017Cowen and CompanyBoost Price TargetMarket Perform$48.00 -> $57.00LowView Rating Details
4/29/2017Evercore ISIReiterated RatingOutperform$57.00 -> $60.00LowView Rating Details
4/28/2017Morgan StanleyBoost Price TargetUnderweight$48.00 -> $52.00LowView Rating Details
4/27/2017Royal Bank of CanadaBoost Price TargetSector Perform -> Sector Perform$55.00 -> $58.00LowView Rating Details
4/27/2017BMO Capital MarketsReiterated RatingHold$55.00LowView Rating Details
4/4/2017Leerink SwannUpgradeMarket Perform -> Outperform$54.00 -> $64.00MediumView Rating Details
2/2/2017Barclays PLCReiterated RatingOverweight$57.00 -> $60.00N/AView Rating Details
10/13/2016Wells Fargo & CoInitiated CoverageOutperformN/AView Rating Details
8/15/2016ArgusReiterated RatingHoldN/AView Rating Details
7/27/2016JPMorgan Chase & Co.Boost Price TargetNeutral$45.00 -> $48.00N/AView Rating Details
6/13/2016Piper Jaffray CompaniesReiterated RatingOverweight$60.00N/AView Rating Details
5/10/2016Credit Suisse Group AGReiterated RatingHoldN/AView Rating Details
7/31/2015S&P Equity ResearchDowngradeHold$42.00N/AView Rating Details
7/13/2015Deutsche Bank AGReiterated RatingHold$66.00 -> $37.00N/AView Rating Details
7/2/2015Bank of America CorpDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Baxter International (NYSE:BAX)
Earnings by Quarter for Baxter International (NYSE:BAX)
Earnings History by Quarter for Baxter International (NYSE:BAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2017Q1 2017$0.51$0.58$2.43 billion$2.48 billionViewN/AView Earnings Details
2/1/2017Q416$0.52$0.57$2.65 billion$2.65 billionViewListenView Earnings Details
10/25/2016Q316$0.45$0.56$2.67 billion$2.56 billionViewListenView Earnings Details
7/26/2016Q216$0.40$0.46$2.51 billion$2.60 billionViewListenView Earnings Details
4/26/2016Q116$0.29$0.36$2.35 billion$2.40 billionViewListenView Earnings Details
2/2/2016Q415$0.32$0.43$2.55 billion$2.60 billionViewListenView Earnings Details
10/27/2015Q315$0.29$0.41$2.46 billion$2.49 billionViewListenView Earnings Details
7/29/2015Q215$0.94$1.00$2.40 billion$3.90 billionViewListenView Earnings Details
4/23/2015Q115$0.88$1.00$3.70 billion$3.76 billionViewListenView Earnings Details
1/29/2015Q414$1.31$1.34$4.37 billion$4.47 billionViewListenView Earnings Details
10/16/2014Q314$1.31$1.31$4.21 billion$4.20 billionViewListenView Earnings Details
7/17/2014Q214$1.21$1.26$4.12 billion$4.30 billionViewListenView Earnings Details
4/17/2014Q114$1.10$1.19$3.88 billion$3.95 billionViewListenView Earnings Details
1/23/2014Q413$1.25$1.26$4.25 billion$4.40 billionViewListenView Earnings Details
10/17/2013Q313$1.19$1.19$3.82 billion$3.80 billionViewListenView Earnings Details
7/18/2013Q2 2013$1.13$1.16$3.70 billion$3.67 billionViewListenView Earnings Details
4/18/2013Q1 2013$1.04$1.05$3.49 billion$3.45 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.26$1.26$3.72 billion$3.75 billionViewListenView Earnings Details
10/18/2012$1.14$1.14ViewN/AView Earnings Details
7/19/2012$1.11$1.12ViewN/AView Earnings Details
4/19/2012$1.00$1.01ViewN/AView Earnings Details
1/26/2012$1.17$1.17ViewN/AView Earnings Details
10/20/2011$1.08$1.09ViewN/AView Earnings Details
7/21/2011$1.02$1.07ViewN/AView Earnings Details
4/21/2011$0.93$0.98ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Baxter International (NYSE:BAX)
2017 EPS Consensus Estimate: $2.18
2018 EPS Consensus Estimate: $2.48
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.50$0.51$0.51
Q2 20172$0.55$0.56$0.56
Q3 20172$0.54$0.55$0.55
Q4 20172$0.56$0.58$0.57
Q1 20182$0.56$0.61$0.59
Q2 20182$0.60$0.63$0.62
Q3 20182$0.61$0.64$0.63
Q4 20182$0.65$0.65$0.65
(Data provided by Zacks Investment Research)


Current Dividend Information for Baxter International (NYSE:BAX)
Next Dividend:7/3/2017
Annual Dividend:$0.52
Dividend Yield:0.89%
Dividend Growth:-36.10% (3 Year Average)
Payout Ratio:5.78% (Trailing 12 Months of Earnings)
22.91% (Based on This Year's Estimates)
20.31% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Baxter International (NYSE:BAX)

Dividend History by Quarter for Baxter International (NYSE:BAX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Baxter International (NYSE:BAX)
Insider Ownership Percentage: 1.08%
Institutional Ownership Percentage: 83.20%
Insider Trades by Quarter for Baxter International (NYSE:BAX)
Institutional Ownership by Quarter for Baxter International (NYSE:BAX)
Insider Trades by Quarter for Baxter International (NYSE:BAX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/23/2017Carole J ShapazianDirectorSell2,618$57.92$151,634.56View SEC Filing  
5/9/2017Carole J ShapazianDirectorSell3,760$55.89$210,146.40View SEC Filing  
5/8/2017Brik V EyreSVPSell130,732$55.69$7,280,465.08View SEC Filing  
4/10/2017Albert P L StrouckenDirectorSell4,280$52.80$225,984.00View SEC Filing  
3/29/2017James R Gavin IIIDirectorSell4,280$51.72$221,361.60View SEC Filing  
2/22/2017Peter S HellmanDirectorSell4,280$49.81$213,186.80View SEC Filing  
2/8/2017John D ForsythDirectorSell4,280$48.35$206,938.00View SEC Filing  
5/23/2016Jose E AlmeidaCEOBuy11,691$42.75$499,790.25View SEC Filing  
5/2/2016John D ForsythDirectorSell1,887$44.38$83,745.06View SEC Filing  
4/4/2016John D ForsythDirectorSell1,887$41.75$78,782.25View SEC Filing  
3/14/2016James R Gavin IIIDirectorSell5,660$40.34$228,324.40View SEC Filing  
2/17/2016Peter S. HellmanDirectorSell5,660$38.35$217,061.00View SEC Filing  
2/11/2016Kornelis J. StormDirectorSell5,660$35.98$203,646.80View SEC Filing  
5/22/2015Carole J ShapazianDirectorSell1,533$67.68$103,753.44View SEC Filing  
4/27/2015James R Gavin IIIDirectorSell4,830$71.06$343,219.80View SEC Filing  
7/25/2014Carole J ShapazianDirectorSell1,645$76.98$126,632.10View SEC Filing  
7/24/2014Thomas T StallkampDirectorSell8,300$76.82$637,606.00View SEC Filing  
7/9/2014Ludwig HantsonVPSell24,693$76.00$1,876,668.00View SEC Filing  
5/2/2014Carole ShapazianDirectorSell5,680$75.28$427,590.40View SEC Filing  
4/23/2014Kees StormDirectorSell5,760$72.45$417,312.00View SEC Filing  
4/21/2014Blake DevittDirectorSell4,334$73.12$316,902.08View SEC Filing  
3/27/2014Sebastian BufalinoVPSell21,600$75.10$1,622,160.00View SEC Filing  
9/12/2013Carole ShapazianDirectorSell1,941$71.58$138,936.78View SEC Filing  
8/1/2013Robert L Parkinson JrCEOSell725,750$73.33$53,219,247.50View SEC Filing  
7/26/2013David P ScharfVPSell55,438$73.79$4,090,770.02View SEC Filing  
7/25/2013James R Gavin IIIDirectorSell5,760$72.82$419,443.20View SEC Filing  
7/24/2013Carole J ShapazianDirectorSell4,320$73.58$317,865.60View SEC Filing  
7/22/2013Robert J HombachCFOSell47,452$73.95$3,509,075.40View SEC Filing  
7/16/2013Phillip L BatchelorVPSell5,850$73.00$427,050.00View SEC Filing  
5/22/2013Blake E DevittDirectorSell1,000$72.34$72,340.00View SEC Filing  
5/20/2013Sebastian J BufalinoVPSell24,000$73.75$1,770,000.00View SEC Filing  
5/17/2013Robert M DavisVPSell130,800$73.00$9,548,400.00View SEC Filing  
9/13/2012Michael J BaughmanVPSell11,500$61.00$701,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Baxter International (NYSE:BAX)
Latest Headlines for Baxter International (NYSE:BAX)
DateHeadline logoTweedy Browne Sells Baxter, Cisco, 3M - May 25 at 9:46 PM featured highlights: Applied Materials, Coherent, Axcelis Technologies, Baxter International, Ultra Clean Holdings, Kelly Services and Ferro - May 25 at 4:44 PM logoMedtronic's focus on surgical products fuels profit beat - May 25 at 4:44 PM logoBaxter International Inc (BAX) Director Carole J. Shapazian Sells 2,618 Shares - May 24 at 8:02 PM logoAlexion stock plummets 9% after top management shake-up - May 23 at 3:55 PM logoAlexion Pharma (ALXN) CFO to Resign at End of August; Head of R&D to Retire - May 23 at 10:51 AM logoVitalConnect Announces Closure of $33 Million Series C Financing - May 23 at 10:51 AM logoBaxter Presents Data at ISPOR Annual Meeting with Focus on Helping Hospitals Improve Patient Care - May 23 at 10:51 AM logoGlobal Nerve Repair Market Revenue Expected to Increase at a CAGR of 11.3% Over the Forecast Period: Future Market Insights - May 22 at 10:35 AM logoQuest Diagnostics Poised on Solid Q1 Results Despite Woes - May 22 at 10:34 AM logoCommonwealth Fund President, David Blumenthal, MD, MPP, Named 2017 Recipient of the William B. Graham Prize for Health Services Research - May 19 at 8:45 PM logoCommonwealth Fund President, David Blumenthal, MD, MPP, Named 2017 Recipient of the William B. Graham Prize ... - Business Wire (press release) - May 19 at 3:45 PM logoBaxter International Inc. -- Moody's rates Baxter's new euro notes Baa2; stable outlook - May 19 at 3:45 PM logoBaxter to Present at the Goldman Sachs 38th Annual Healthcare Conference - May 19 at 9:15 AM logoBaxter Launches New AK 98 Hemodialysis System Designed to Help Providers Reach Treatment Goals - Business Wire (press release) - May 18 at 11:51 AM logoBaxter Launches New AK 98 Hemodialysis System Designed to Help Providers Reach Treatment Goals - May 18 at 11:51 AM logoBaxter International Inc (BAX) Research Coverage Started at Goldman Sachs Group Inc - May 16 at 8:56 PM logoNo, Dan Loeb Hasn’t Saved Snap Inc (SNAP) Stock - May 16 at 12:21 PM logoMasimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up - May 12 at 4:24 PM logoBaxter International Inc (BAX) Receives Consensus Rating of "Buy" from Brokerages - May 12 at 10:36 AM logoDull Q1 Earnings & Tough Industry Spell Trouble for BioScrip - May 11 at 4:19 PM logoGenomic Health (GHDX) Misses Q1 Earnings & Sales Estimates - May 11 at 4:19 PM logo$2.59 Billion in Sales Expected for Baxter International Inc (BAX) This Quarter - May 11 at 10:00 AM logoBaxter International Inc (BAX) Director Sells $210,146.40 in Stock - May 10 at 11:44 PM logoBaxter Named One of America's Best Employers by Forbes Magazine for Third Consecutive Year - Business Wire (press release) - May 10 at 8:55 AM logo Analysts Anticipate Baxter International Inc (BAX) Will Announce Earnings of $0.57 Per Share - May 9 at 10:20 PM logoETFs with exposure to Baxter International, Inc. : May 9, 2017 - May 9 at 8:52 PM logoBaxter International Inc (BAX) SVP Brik V. Eyre Sells 130,732 Shares - May 9 at 7:21 PM logoBaxter Named One of America’s Best Employers by Forbes Magazine for Third Consecutive Year - May 9 at 3:51 PM logoPetMed (PETS) Beats Earnings, Revenue Estimates in Q4 - May 9 at 3:51 PM logoPhibro (PAHC) Posts In Line Earnings in Q3, Revises View - May 9 at 8:55 AM logoBaxter International, Inc. :BAX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 8, 2017 - May 8 at 3:43 PM logoVWR Corp (VWR) Beats on Q1 Earnings, Awaits Merger Closure - May 8 at 10:39 AM logoQiagen Banks on Molecular Diagnostic amid Currency Woes - May 8 at 10:38 AM logoAlign Technology Invisalign Sales Strong, Currency Woes Stay - May 8 at 10:38 AM logoBRIEF-Baxter International says in April became aware of criminal investigation by antitrust division of DOJ- SEC filing - May 5 at 8:51 PM logoBaxter International Inc (BAX) - May 5 at 8:51 PM logoOmnicell (OMCL) Q1 Loss Narrower than Expected, Revenues Lag - May 5 at 3:49 PM logoBioScrip (BIOS) Q1 Loss Narrower than Expected, Sales Miss - May 5 at 3:49 PM logoJustice Department Investigating Baxter Over Saline Shortage - Wall Street Journal (subscription) - May 4 at 8:58 PM logo[$$] Justice Department Investigating Baxter Over Saline Shortage - May 4 at 8:58 PM logoFavorable Press Coverage Somewhat Likely to Affect Baxter International (BAX) Stock Price - May 4 at 4:26 PM logoBaxter International Reaches Analyst Target Price - Nasdaq - May 4 at 3:56 PM logoBaxter (BAX) Receives FDA Guidance on Regulatory Pathway for ... - - May 3 at 8:56 PM logoBaxter Achieves Regulatory Milestone for New Peritoneal Dialysis Technology - May 3 at 12:24 PM logoMyriad Genetics (MYGN) Tops Q3 Earnings & Sales, Tweaks View - May 3 at 12:24 PM logoBet on Relative Price Performance with These 5 Stocks - May 3 at 12:24 PM logoBaxter International Inc (BAX) Raises Dividend to $0.16 Per Share - May 2 at 12:46 PM logoBRIEF-Baxter raises quarterly dividend - May 2 at 10:48 AM logoBaxter Raises Quarterly Dividend - May 2 at 10:48 AM



Baxter International (BAX) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff